This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Oxymera

PhaseBio Pharmaceuticals, Inc.

Drug Names(s): oxyntomodulin analogue

Description: Oxymera is a recombinant analogue of oxyntomodulin genetically fused with an ELP biopolymer and manufactured in E. coli. This formulation increases metabolic rate and energy expenditure, with improved half-life for reduced dosing frequency.

Oxyntomodulin is thought to act as both a GLP-1 and glucagon agonist. While glucagon agonism can counteract the glucose lowering effects of GLP-1, weight loss from glucagon agonism may counteract this to lead to further lowering of glucose.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug